Table 2.
Drug resistance pattern of major Gram-positive isolates.
| Antimicrobial tested | Enterococcus (n = 5) | Staphylococcus aureus (n = 51) | ||
|---|---|---|---|---|
| Mini API (n = 3) | Vitek (n = 2) | Mini API (n = 21) | Vitek (n = 30) | |
| Amoxicillin | NP | NP | 100 | 100 |
| Cefotaxime + clavulanate | NP | 50 | NP | 37 |
| Ceftazidime + clavulanate | NP | 50 | NP | 37 |
| Cefepime + tazobactam | NP | 50 | NP | 30 |
| Tigecycline | NP | 0 | NP | NP |
| Gentamycin | 33 | 50 | NP | NP |
| Amikacin | 33 | 50 | NP | NP |
| Ciproflox | 100 | 100 | 90 | 87 |
| Levoflox | 100 | 100 | 75 | 80 |
| Nalidixic acid | 100 | 100 | NP | NP |
| Nitrofurantoin | 100 | 100 | 0 | 78 |
| Tetracycline | 33 | 50 | 10 | 27 |
| Doxycycline | 33 | 50 | 10 | 27 |
| Minocycline | 33 | 50 | 10 | 27 |
| Oxacillin | NP | NP | 73 | 67 |
| Vancomycin** | 50 | 50 | 20 | 22 |
| Teicoplanin | 33 | 50 | NP | 0 |
| Daptomycin | NP | 0 | NP | 6 |
| Linezolid | NP | 0 | NP | 3 |
NP: drug not in panel; **see Section 4.
Figures in the table are expressed in percentages.